StreetInsider.com News Articles

Bristol Myers Squibb partners with Microsoft on AI lung cancer detection

Tue, 20 Jan 2026 06:59:42 -0500

Bristol Myers Squibb (NYSE: BMY) announced a collaboration with Microsoft to deploy AI algorithms for early lung cancer detection through Microsoft's Precision Imaging Network.

The partnership will integrate U.S. FDA-cleared radiology AI algorithms into Microsoft's healthcare radiology solutions, which are used by more than 80% of U.S. hospitals. The AI technology analyzes X-ray and CT images to identify lung disease and detect lung nodules that may indicate early-stage lung cancer.

Lung cancer causes approximately 125,000 deaths annually in the United States, with 227,000 new cases reported each year. The collaboration aims to address disparities in care, as medically underserved populations experience higher

Bristol Myers Squibb partners with Microsoft on AI lung cancer detection

Tue, 20 Jan 2026 06:59:42 -0500

Bristol Myers Squibb (NYSE: BMY) announced a collaboration with Microsoft to deploy AI algorithms for early lung cancer detection through Microsoft's Precision Imaging Network.

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY, “BMS”), a global leader in oncology, today announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to accelerate early detection of lung cancer.

Through this digital health collaboration, U.S. FDA-cleared radiology AI algorithms will be deployed via Microsoft’s Precision Imaging Network, part of Microsoft for Healthcare radiology solutions. Today, more than 80% of hospitals

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer

Tue, 20 Jan 2026 06:59:00 -0500

Joint initiative to focus on expanding early detection and equitable access to care through lung cancer specific AI workflows on Microsoft’s suite of radiology solutions

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY, “BMS”) today announced an agreement with the U.S. government to provide Eliquis® (apixaban), an oral anticoagulant relied upon by millions of Americans daily, for free to the Medicaid program and to donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to ensure American supply chain resilience. The agreement is aligned with BMS’s ongoing commitment to advancing cardiovascular health, improving

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans

Fri, 19 Dec 2025 15:05:00 -0500

Eliquis® (apixaban), the Nation’s #1 Prescribed Oral Blood Thinner, Soon Available for Free to Medicaid Program

Agreement Provides Tariff Relief for a 3-Year Period

Bristol Myers Squibb continues alzheimer's psychosis study after site review

Wed, 03 Dec 2025 06:59:13 -0500